Brief: Poxel Says PXL770 Awarded FDA Fast Track Designation For X-Linked Adrenoleukodystrophy

Poxel SA

11/04/2022 16:49

April 11 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES PXL770 AWARDED FDA FAST TRACK DESIGNATION
FOR
X-LINKED ADRENOLEUKODYSTROPHY
    * IS PLEASED TO ANNOUNCE THAT U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) HAS GRANTED FAST TRACK DESIGNATION (FTD) TO PXL770 FOR
TREATMENT OF PATIENTS WITH ADRENOMYELONEUROPATHY (AMN)
    * WE ARE PREPARING NEXT STEPS TO INITIATE OUR TWO PHASE 2A
CLINICAL STUDIES MIDYEAR, WITH RESULTS ANTICIPATED EARLY 2023

Source text for Eikon:  ID:nBw194KL1a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))